Skip to main content
. 2022 Jul 7;63:101533. doi: 10.1016/j.molmet.2022.101533

Figure 3.

Figure 3

Triple receptor agonism of GLP-1R, GIPR, and GcgR produces superior body weight lowering efficacy compared to GLP-1/GIPR co-agonist tirzpatide in DIO mice. Body weight (A) and food intake (B) for DIO mice given subcutaneous injections once per day with tirzepatide or GLP-1R/GIPR/GcgR triple agonist 16. Dosing concentrations and dose-escalation schedule is provided in panel C. Average starting body weight for mice in these studies was 61.2 g and did not differ significantly between any group. ∗ indicate a p-value < 0.05 compared to vehicle control; ˆ indicate a p-value < 0.05 relative to the equimolar dose of tirzepatide as indicated.